Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations
- 5 April 2021
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 75 (7) , 488-492
Abstract
Aims: In metastatic colorectal carcinomas (mCRC), RAS / RAF genes mutations are first tested to determine the eligibility for anti-EGFR (Epidermal Growth Factor Receptor) therapy in combination with conventional cytotoxic agents. Recent advancements in next-generation sequencing (NGS) have highlighted the potential of multi-gene panels. This multi-gene analysis may provide useful information for the molecular characterisation of mCRC, other than the status of RAS/RAF genes. Aim of this study was to evaluate the feasibility of two NGS custom multi-gene panels in the characterisation of CRC cases and evaluating the relevance of PIK3CA mutation in a routine cohort of consecutive CRC cases. Methods: A total of 961 formalin-fixed and paraffin-embedded specimens from two medical centres (Bologna and Naples) were analysed using two lab-developed NGS multi-gene panels. Results: KRAS mutations (56.2%) were the more frequent alterations observed in our cohort. Intriguingly, PIK3CA mutations were more frequent (16.8%) than variants observed in the other two genes nowadays analysed in CRC clinical practice ( NRAS and BRAF , 4.2% and 9.6%, respectively). Moreover, in more than 10% of samples, coexistent mutations were detected in our cohort of CRC. Conclusions: Our study demonstrates the feasibility and efficacy of lab-developed targeted multi-gene NGS panels in the clinical practice of CRC. Moreover, the data lead to hypothesise that PIK3CA mutations, together with those of RAS / BRAF , worth to be further investigated in clinical CRC specimens.Keywords
This publication has 30 references indexed in Scilit:
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cellsInternational Journal of Cancer, 2013
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Oncogenic Mutations of PIK3CA in Human Cancers2010
- PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon CancerJournal of Clinical Oncology, 2009
- Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern populationOncogene, 2008
- Mutations of the PIK3CA gene in hereditary colorectal cancersInternational Journal of Cancer, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1Oncogene, 2005
- The prevalence of PIK3CA mutations in gastric and colon cancerEuropean Journal of Cancer, 2005
- Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinomaCancer, 2002